TY  - CONF
AU  - Erić, Katarina
AU  - Miladinov, Marko
AU  - Dragičević, Sandra
AU  - Rosić, Jovana
AU  - Barišić, Goran
AU  - Marković, Velimir
AU  - Zeljić, Katarina
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2099
AB  - Patients with locally advanced rectal cancer are mainly treated with chemoradiotherapy (CRT) before
surgery. Less than 20% of patients respond completely to neoadjuvant CRT. To avoid unnecessary treatment, biomarkers
are being sought to identi fy pati ents with rectal cancer who do not respond to therapy. The HOX Transcript Anti sense
Intergenic RNA (HOTAIR) is a long non-coding trans-acti ng RNA molecule that is frequently deregulated in cancers of
the digestive tract and plays a role in chemoresistance. The aim of this study was to investigate HOTAIR as a potential
biomarker for predicting treatment response in patients with rectal cancer.
PB  - Belgrade :  Serbian Association on for Cancer Research
C3  - 6th Congress of the Serbian Association for Cancer Research (SDIR)
T1  - Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy
EP  - 82
IS  - 1
SP  - 82
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2099
ER  - 

@conference{
author = "Erić, Katarina and Miladinov, Marko and Dragičević, Sandra and Rosić, Jovana and Barišić, Goran and Marković, Velimir and Zeljić, Katarina",
year = "2023",
abstract = "Patients with locally advanced rectal cancer are mainly treated with chemoradiotherapy (CRT) before
surgery. Less than 20% of patients respond completely to neoadjuvant CRT. To avoid unnecessary treatment, biomarkers
are being sought to identi fy pati ents with rectal cancer who do not respond to therapy. The HOX Transcript Anti sense
Intergenic RNA (HOTAIR) is a long non-coding trans-acti ng RNA molecule that is frequently deregulated in cancers of
the digestive tract and plays a role in chemoresistance. The aim of this study was to investigate HOTAIR as a potential
biomarker for predicting treatment response in patients with rectal cancer.",
publisher = "Belgrade :  Serbian Association on for Cancer Research",
journal = "6th Congress of the Serbian Association for Cancer Research (SDIR)",
title = "Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy",
pages = "82-82",
number = "1",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2099"
}

Erić, K., Miladinov, M., Dragičević, S., Rosić, J., Barišić, G., Marković, V.,& Zeljić, K.. (2023). Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy. in 6th Congress of the Serbian Association for Cancer Research (SDIR)
Belgrade :  Serbian Association on for Cancer Research.(1), 82-82.
https://hdl.handle.net/21.15107/rcub_imagine_2099

Erić K, Miladinov M, Dragičević S, Rosić J, Barišić G, Marković V, Zeljić K. Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy. in 6th Congress of the Serbian Association for Cancer Research (SDIR). 2023;(1):82-82.
https://hdl.handle.net/21.15107/rcub_imagine_2099 .

Erić, Katarina, Miladinov, Marko, Dragičević, Sandra, Rosić, Jovana, Barišić, Goran, Marković, Velimir, Zeljić, Katarina, "Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy" in 6th Congress of the Serbian Association for Cancer Research (SDIR), no. 1 (2023):82-82,
https://hdl.handle.net/21.15107/rcub_imagine_2099 .

TY  - CONF
AU  - Erić, K.
AU  - Rosić, Jovana
AU  - Miladinov, Marko
AU  - Dragičević, Sandra
AU  - Barišić, Goran
AU  - Marković, V.
AU  - Zeljić, Katarina
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2081
AB  - Background & objectives: The NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) gene encodes a long non-coding RNA that is deregulated in carcinomas of the gastrointestinal tract. Diagnostic and predictive potential of NEAT1 was investigated in patients with locally
advanced rectal cancer.
Methods: The study group consisted of 19 patients with rectal cancer
treated with neoadjuvant chemoradiotherapy (nCRT). RNA was isolated with TRIzol reagent from samples of rectal cancer and noncancerous tissue before and after nCRT. The relative expression level of
NEAT1 normalised to GAPDH was determined by qRT-PCR method.
Results: Expression of NEAT1 did not difer between rectal cancer and
noncancerous tissue before nCRT (p=0.953) and cancer and noncancerous tissue after nCRT (p=0.210). There was no diference in NEAT1
expression between tumour tissue before and after nCRT (p=0.079).
NEAT1 was signifcantly higher in noncancerous tissue before than
after nCRT (p=0.005). Therapy responders (TRG1, TRG2) and nonresponders (TRG3, TRG4) did not difer in NEAT1 levels in tumour
tissue before (p=0.790) and after nCRT (p=0.352). NEAT1 expression
in rectal cancer tissue before nCRT cannot be used as a biomarker to
distinguish responders from non-responders (AUC=0.559, 95%CI=0-
1, p=0.790). Demographic and clinicopathological characteristics were
not associated with NEAT1 expression in rectal cancer tissue.
Conclusion: The obtained results suggest that the long noncoding
RNA NEAT1 cannot be considered as a biomarker with diagnostic
potential or for predicting response to nCRT in patients with rectal
cancer. Validation of the current results in a larger group of patients
with locally advanced rectal cancer is warranted.
PB  - Springer
C3  - Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September
T1  - Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer
EP  - S307
IS  - Supplement 1
SP  - S307
SP  - E-PS-15-011
VL  - 483
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2081
ER  - 

@conference{
author = "Erić, K. and Rosić, Jovana and Miladinov, Marko and Dragičević, Sandra and Barišić, Goran and Marković, V. and Zeljić, Katarina",
year = "2023",
abstract = "Background & objectives: The NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) gene encodes a long non-coding RNA that is deregulated in carcinomas of the gastrointestinal tract. Diagnostic and predictive potential of NEAT1 was investigated in patients with locally
advanced rectal cancer.
Methods: The study group consisted of 19 patients with rectal cancer
treated with neoadjuvant chemoradiotherapy (nCRT). RNA was isolated with TRIzol reagent from samples of rectal cancer and noncancerous tissue before and after nCRT. The relative expression level of
NEAT1 normalised to GAPDH was determined by qRT-PCR method.
Results: Expression of NEAT1 did not difer between rectal cancer and
noncancerous tissue before nCRT (p=0.953) and cancer and noncancerous tissue after nCRT (p=0.210). There was no diference in NEAT1
expression between tumour tissue before and after nCRT (p=0.079).
NEAT1 was signifcantly higher in noncancerous tissue before than
after nCRT (p=0.005). Therapy responders (TRG1, TRG2) and nonresponders (TRG3, TRG4) did not difer in NEAT1 levels in tumour
tissue before (p=0.790) and after nCRT (p=0.352). NEAT1 expression
in rectal cancer tissue before nCRT cannot be used as a biomarker to
distinguish responders from non-responders (AUC=0.559, 95%CI=0-
1, p=0.790). Demographic and clinicopathological characteristics were
not associated with NEAT1 expression in rectal cancer tissue.
Conclusion: The obtained results suggest that the long noncoding
RNA NEAT1 cannot be considered as a biomarker with diagnostic
potential or for predicting response to nCRT in patients with rectal
cancer. Validation of the current results in a larger group of patients
with locally advanced rectal cancer is warranted.",
publisher = "Springer",
journal = "Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September",
title = "Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer",
pages = "S307-S307-E-PS-15-011",
number = "Supplement 1",
volume = "483",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2081"
}

Erić, K., Rosić, J., Miladinov, M., Dragičević, S., Barišić, G., Marković, V.,& Zeljić, K.. (2023). Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer. in Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September
Springer., 483(Supplement 1), S307-S307.
https://hdl.handle.net/21.15107/rcub_imagine_2081

Erić K, Rosić J, Miladinov M, Dragičević S, Barišić G, Marković V, Zeljić K. Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer. in Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September. 2023;483(Supplement 1):S307-S307.
https://hdl.handle.net/21.15107/rcub_imagine_2081 .

Erić, K., Rosić, Jovana, Miladinov, Marko, Dragičević, Sandra, Barišić, Goran, Marković, V., Zeljić, Katarina, "Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer" in Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September, 483, no. Supplement 1 (2023):S307-S307,
https://hdl.handle.net/21.15107/rcub_imagine_2081 .

TY  - JOUR
AU  - Rosić, Jovana
AU  - Miladinov, Marko
AU  - Dragičević, Sandra
AU  - Erić, Katarina
AU  - Bogdanović, Aleksandar
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1769
AB  - Considering the impact of SMAD7 deregulation in colorectal cancer (CRC) progression and the
significance of single nucleotide variant (SNV)-mediated disruptions of microRNA (miRNA)-dependent regulation
for cancer susceptibility, our study aimed to analyze genetic variation in the SMAD7 3′ untranslated region (
3′UTR) in CRC, measure differences in allelic mRNA expression, and evaluate its interference with miRNAmediated
post-transcriptional regulation.
Patients and Methods: This study included 80 patients with different CRC stages and six human colon cancer cell
lines of various histological origins. SMAD7 3′ UTR was analyzed by direct sequencing, followed by the relative
quantification of differential allelic expression of detected variants by allele-specific qRT-PCR. In silico tools were
employed for predictions of regulatory consequences of detected variants.
Results: A total of four different SNVs in one cell line and nine patients were found, among which were a novel
somatic point variant and three already known germline variants (rs16950113, rs1050799536, and
rs1043778717). All evaluated SNVs exhibited variable extents of allelic imbalance in expression. In silico analysis
predicted significant effects of SNVs on miRNA binding efficiency, with each SNV disrupting existing and
creating new target sites for one or more miRNAs.
Conclusion: Imbalance observed in the expression of SNV alleles altering miRNA binding suggests that all
investigated SNVs are potential contributing factors impacting SMAD7 expression regulation in CRC that further
studies should investigate.
PB  - Elsevier
T2  - Gene
T1  - Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance
SP  - 147217
VL  - 859
DO  - doi.org/10.1016/j.gene.2023.147217
ER  - 

@article{
author = "Rosić, Jovana and Miladinov, Marko and Dragičević, Sandra and Erić, Katarina and Bogdanović, Aleksandar and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2023",
abstract = "Considering the impact of SMAD7 deregulation in colorectal cancer (CRC) progression and the
significance of single nucleotide variant (SNV)-mediated disruptions of microRNA (miRNA)-dependent regulation
for cancer susceptibility, our study aimed to analyze genetic variation in the SMAD7 3′ untranslated region (
3′UTR) in CRC, measure differences in allelic mRNA expression, and evaluate its interference with miRNAmediated
post-transcriptional regulation.
Patients and Methods: This study included 80 patients with different CRC stages and six human colon cancer cell
lines of various histological origins. SMAD7 3′ UTR was analyzed by direct sequencing, followed by the relative
quantification of differential allelic expression of detected variants by allele-specific qRT-PCR. In silico tools were
employed for predictions of regulatory consequences of detected variants.
Results: A total of four different SNVs in one cell line and nine patients were found, among which were a novel
somatic point variant and three already known germline variants (rs16950113, rs1050799536, and
rs1043778717). All evaluated SNVs exhibited variable extents of allelic imbalance in expression. In silico analysis
predicted significant effects of SNVs on miRNA binding efficiency, with each SNV disrupting existing and
creating new target sites for one or more miRNAs.
Conclusion: Imbalance observed in the expression of SNV alleles altering miRNA binding suggests that all
investigated SNVs are potential contributing factors impacting SMAD7 expression regulation in CRC that further
studies should investigate.",
publisher = "Elsevier",
journal = "Gene",
title = "Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance",
pages = "147217",
volume = "859",
doi = "doi.org/10.1016/j.gene.2023.147217"
}

Rosić, J., Miladinov, M., Dragičević, S., Erić, K., Bogdanović, A., Krivokapić, Z.,& Nikolić, A.. (2023). Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance. in Gene
Elsevier., 859, 147217.
https://doi.org/doi.org/10.1016/j.gene.2023.147217

Rosić J, Miladinov M, Dragičević S, Erić K, Bogdanović A, Krivokapić Z, Nikolić A. Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance. in Gene. 2023;859:147217.
doi:doi.org/10.1016/j.gene.2023.147217 .

Rosić, Jovana, Miladinov, Marko, Dragičević, Sandra, Erić, Katarina, Bogdanović, Aleksandar, Krivokapić, Zoran, Nikolić, Aleksandra, "Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance" in Gene, 859 (2023):147217,
https://doi.org/doi.org/10.1016/j.gene.2023.147217 . .

TY  - CONF
AU  - Erić, K.
AU  - Miladinov, Marko
AU  - Dragičević, Sandra
AU  - Rosić, Jovana
AU  - Krivokapić, Zoran
AU  - Zeljić, Katarina
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2083
AB  - Background & objectives: Long non coding RNA, H19 is an imprinted, maternally expressed gene, usually deregulated in diferent cancer types, including rectal cancer. This study aimed to investigate H19 role as a potential biomarker to predict therapy response in rectal cancer patients. Methods: The study included 14 patients diagnosed with rectal cancer, treated with neoadjuvant chemoradio therapy (nCRT). RNA was isolated by TRIzol reagent from samples of rectal cancer tissue  before and after nCRT. Relative expression of H19 was normal- ized to housekeeping GAPDH gene, and expression was analysed  by quantitative real-time PCR. Relative expression of H19 was calculated by 2-ΔCt method. Results: Relative expression of H19 was significantly increased in rectal cancer tissue after nCRT (0.244±0.408) compared to the tissue before nCRT (0.043±0.055), p=0.004, Wilcoxon test. According to tumour regression grade (TRG), 85.71% (12/14) of  patients did not respond, while 14.28% (2/14) responded to pre- operative CRT. Responders (TRG1, TRG2) and non-responders  (TRG3, TRG4) did not differ in H19 expression in tumour tissue before (p=0.659, Mann-Whitney U test) as well as after nCRT  (p=0.999, Mann-Whitney U test). Receiver operating curve analy- sis indicates that H19 expression in colorectal tissue before nCRT  can not be used as a biomarker for distinguishing responders from non-responders (AUC=0.625, 95%CI=0.257-0.992, p=0.583).  Conclusion: Our study suggests H19 upregulation upon neoadju- vant chemoradiotherapy in rectal cancer. The potential predictive  value of H19 as a biomarker of therapy response should be studied in a larger group of patients.
PB  - Springer
C3  - Virchows Archiv, 34 th European Congress of Pathology - Abstracts
T1  - Long non-coding RNA H19 expression in rectal cancer and therapy response
EP  - S145
IS  - Supplement 1
SP  - S145
SP  - PS-15-017
VL  - 481
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2083
ER  - 

@conference{
author = "Erić, K. and Miladinov, Marko and Dragičević, Sandra and Rosić, Jovana and Krivokapić, Zoran and Zeljić, Katarina",
year = "2022",
abstract = "Background & objectives: Long non coding RNA, H19 is an imprinted, maternally expressed gene, usually deregulated in diferent cancer types, including rectal cancer. This study aimed to investigate H19 role as a potential biomarker to predict therapy response in rectal cancer patients. Methods: The study included 14 patients diagnosed with rectal cancer, treated with neoadjuvant chemoradio therapy (nCRT). RNA was isolated by TRIzol reagent from samples of rectal cancer tissue  before and after nCRT. Relative expression of H19 was normal- ized to housekeeping GAPDH gene, and expression was analysed  by quantitative real-time PCR. Relative expression of H19 was calculated by 2-ΔCt method. Results: Relative expression of H19 was significantly increased in rectal cancer tissue after nCRT (0.244±0.408) compared to the tissue before nCRT (0.043±0.055), p=0.004, Wilcoxon test. According to tumour regression grade (TRG), 85.71% (12/14) of  patients did not respond, while 14.28% (2/14) responded to pre- operative CRT. Responders (TRG1, TRG2) and non-responders  (TRG3, TRG4) did not differ in H19 expression in tumour tissue before (p=0.659, Mann-Whitney U test) as well as after nCRT  (p=0.999, Mann-Whitney U test). Receiver operating curve analy- sis indicates that H19 expression in colorectal tissue before nCRT  can not be used as a biomarker for distinguishing responders from non-responders (AUC=0.625, 95%CI=0.257-0.992, p=0.583).  Conclusion: Our study suggests H19 upregulation upon neoadju- vant chemoradiotherapy in rectal cancer. The potential predictive  value of H19 as a biomarker of therapy response should be studied in a larger group of patients.",
publisher = "Springer",
journal = "Virchows Archiv, 34 th European Congress of Pathology - Abstracts",
title = "Long non-coding RNA H19 expression in rectal cancer and therapy response",
pages = "S145-S145-PS-15-017",
number = "Supplement 1",
volume = "481",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2083"
}

Erić, K., Miladinov, M., Dragičević, S., Rosić, J., Krivokapić, Z.,& Zeljić, K.. (2022). Long non-coding RNA H19 expression in rectal cancer and therapy response. in Virchows Archiv, 34 th European Congress of Pathology - Abstracts
Springer., 481(Supplement 1), S145-S145.
https://hdl.handle.net/21.15107/rcub_imagine_2083

Erić K, Miladinov M, Dragičević S, Rosić J, Krivokapić Z, Zeljić K. Long non-coding RNA H19 expression in rectal cancer and therapy response. in Virchows Archiv, 34 th European Congress of Pathology - Abstracts. 2022;481(Supplement 1):S145-S145.
https://hdl.handle.net/21.15107/rcub_imagine_2083 .

Erić, K., Miladinov, Marko, Dragičević, Sandra, Rosić, Jovana, Krivokapić, Zoran, Zeljić, Katarina, "Long non-coding RNA H19 expression in rectal cancer and therapy response" in Virchows Archiv, 34 th European Congress of Pathology - Abstracts, 481, no. Supplement 1 (2022):S145-S145,
https://hdl.handle.net/21.15107/rcub_imagine_2083 .

TY  - JOUR
AU  - Babić, Tamara
AU  - Lygirou, Vasiliki
AU  - Rosić, Jovana
AU  - Miladinov, Marko
AU  - Rom, Aleksandra Djikic
AU  - Baira, Eirini
AU  - Stroggilos, Rafael
AU  - Pappa, Eftychia
AU  - Zoidakis, Jerome
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1521
AB  - Purpose In the search for candidate predictive biomarkers to evaluate response to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer, only a few studies report proteomic profiles of tumor tissue before and after nCRT. The aim of our study was to determine differentially expressed proteins between responders and non-responders before and after the therapy in order to identify candidate molecules for prediction and follow-up of response to nCRT. Experimental Design The study has included tissue sections of rectal tumor and non-tumor mucosa from five responders and five non-responders taken before and after nCRT from patients with locally advanced rectal cancer. Extracted proteins were analyzed by LC-MS/MS analysis followed by a set of bioinformatics analyses. Result Proteomics analysis provided a mean of approximately 1050 protein identifications per sample. A comparison of proteomic profiles between responders and non-responders has identified 18 differentially expressed proteins. Pathway analysis demonstrated high metabolic activity in non-responders' tumors before nCRT, indicating the presence of intrinsic chemoradioresistance in these subjects. Two proteins associated with poor prognosis in colorectal cancer, ADAM10 and CAD, were identified as candidate predictive biomarkers as they were present in non-responders only. Conclusions and Clinical Relevance Shortlisted proteins from our study should be further validated as candidate biomarkers for response to routinely applied nCRT protocols.
PB  - Wiley-V C H Verlag Gmbh, Weinheim
T2  - Proteomics Clinical Applications
T1  - Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue
DO  - 10.1002/prca.202100116
ER  - 

@article{
author = "Babić, Tamara and Lygirou, Vasiliki and Rosić, Jovana and Miladinov, Marko and Rom, Aleksandra Djikic and Baira, Eirini and Stroggilos, Rafael and Pappa, Eftychia and Zoidakis, Jerome and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2022",
abstract = "Purpose In the search for candidate predictive biomarkers to evaluate response to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer, only a few studies report proteomic profiles of tumor tissue before and after nCRT. The aim of our study was to determine differentially expressed proteins between responders and non-responders before and after the therapy in order to identify candidate molecules for prediction and follow-up of response to nCRT. Experimental Design The study has included tissue sections of rectal tumor and non-tumor mucosa from five responders and five non-responders taken before and after nCRT from patients with locally advanced rectal cancer. Extracted proteins were analyzed by LC-MS/MS analysis followed by a set of bioinformatics analyses. Result Proteomics analysis provided a mean of approximately 1050 protein identifications per sample. A comparison of proteomic profiles between responders and non-responders has identified 18 differentially expressed proteins. Pathway analysis demonstrated high metabolic activity in non-responders' tumors before nCRT, indicating the presence of intrinsic chemoradioresistance in these subjects. Two proteins associated with poor prognosis in colorectal cancer, ADAM10 and CAD, were identified as candidate predictive biomarkers as they were present in non-responders only. Conclusions and Clinical Relevance Shortlisted proteins from our study should be further validated as candidate biomarkers for response to routinely applied nCRT protocols.",
publisher = "Wiley-V C H Verlag Gmbh, Weinheim",
journal = "Proteomics Clinical Applications",
title = "Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue",
doi = "10.1002/prca.202100116"
}

Babić, T., Lygirou, V., Rosić, J., Miladinov, M., Rom, A. D., Baira, E., Stroggilos, R., Pappa, E., Zoidakis, J., Krivokapić, Z.,& Nikolić, A.. (2022). Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue. in Proteomics Clinical Applications
Wiley-V C H Verlag Gmbh, Weinheim..
https://doi.org/10.1002/prca.202100116

Babić T, Lygirou V, Rosić J, Miladinov M, Rom AD, Baira E, Stroggilos R, Pappa E, Zoidakis J, Krivokapić Z, Nikolić A. Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue. in Proteomics Clinical Applications. 2022;.
doi:10.1002/prca.202100116 .

Babić, Tamara, Lygirou, Vasiliki, Rosić, Jovana, Miladinov, Marko, Rom, Aleksandra Djikic, Baira, Eirini, Stroggilos, Rafael, Pappa, Eftychia, Zoidakis, Jerome, Krivokapić, Zoran, Nikolić, Aleksandra, "Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue" in Proteomics Clinical Applications (2022),
https://doi.org/10.1002/prca.202100116 . .

TY  - JOUR
AU  - Bogdanović, Aleksandar
AU  - Despotović, Jovana
AU  - Galun, Danijel
AU  - Bidzić, Nemanja
AU  - Nikolić, Aleksandra
AU  - Rosić, Jovana
AU  - Krivokapić, Zoran
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1490
AB  - Purpose: There are limited data on expression of epithelial-mesenchymal transition (EMT) markers in patients with colorectal liver metastases (CRLM). The study aim was to evaluate the expression and prognostic significance of E-cadherin (CDH1), fibronectin (FN1) and vimentin (VIM) in patients with CRLM after curative-intent liver resection. Patients and Methods: Thirty patients with CRLM managed by curative-intent liver resection were included in this prospective pilot study. Blood samples, colorectal liver metastases and surrounding non-tumor liver tissue were collected. Expression of CDH1, FN1 and VIM was analyzed by quantitative real-time polymerase chain reaction. Expression in CRLM and non-tumor liver tissue was compared, while expression in serum was correlated with CRLM expression. One-year recurrence-free survival was compared between patients with low and high CDH1, FN1 and VIM expression. Results: The expression of CDH1 was similar in CRLM and non-tumor liver tissues, while FN1 and VIM expression was significantly lower in metastatic tissue (P=0.003 and pP lt  0.001, respectively). Serum expression of CDH1 and VIM was detected in 66.7% and 93.3% of patients, respectively, while FN1 was not detected in any of the patients. The correlation of CDH1 and VIM expression between CRLM and serum was not statistically significant. Decreased CDH1 expression in CRLM and decreased VIM expression in serum were associated with early recurrence after surgical treatment of CRLM. Conclusion: Lower expression of CDH1 in CRLM and lower serum expression of VIM were found to be associated with early recurrence after liver resection for CRLM.
PB  - Dove Medical Press Ltd, Albany
T2  - Cancer Management and Research
T1  - Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection
EP  - 171
SP  - 163
VL  - 13
DO  - 10.2147/CMAR.S287974
ER  - 

@article{
author = "Bogdanović, Aleksandar and Despotović, Jovana and Galun, Danijel and Bidzić, Nemanja and Nikolić, Aleksandra and Rosić, Jovana and Krivokapić, Zoran",
year = "2021",
abstract = "Purpose: There are limited data on expression of epithelial-mesenchymal transition (EMT) markers in patients with colorectal liver metastases (CRLM). The study aim was to evaluate the expression and prognostic significance of E-cadherin (CDH1), fibronectin (FN1) and vimentin (VIM) in patients with CRLM after curative-intent liver resection. Patients and Methods: Thirty patients with CRLM managed by curative-intent liver resection were included in this prospective pilot study. Blood samples, colorectal liver metastases and surrounding non-tumor liver tissue were collected. Expression of CDH1, FN1 and VIM was analyzed by quantitative real-time polymerase chain reaction. Expression in CRLM and non-tumor liver tissue was compared, while expression in serum was correlated with CRLM expression. One-year recurrence-free survival was compared between patients with low and high CDH1, FN1 and VIM expression. Results: The expression of CDH1 was similar in CRLM and non-tumor liver tissues, while FN1 and VIM expression was significantly lower in metastatic tissue (P=0.003 and pP lt  0.001, respectively). Serum expression of CDH1 and VIM was detected in 66.7% and 93.3% of patients, respectively, while FN1 was not detected in any of the patients. The correlation of CDH1 and VIM expression between CRLM and serum was not statistically significant. Decreased CDH1 expression in CRLM and decreased VIM expression in serum were associated with early recurrence after surgical treatment of CRLM. Conclusion: Lower expression of CDH1 in CRLM and lower serum expression of VIM were found to be associated with early recurrence after liver resection for CRLM.",
publisher = "Dove Medical Press Ltd, Albany",
journal = "Cancer Management and Research",
title = "Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection",
pages = "171-163",
volume = "13",
doi = "10.2147/CMAR.S287974"
}

Bogdanović, A., Despotović, J., Galun, D., Bidzić, N., Nikolić, A., Rosić, J.,& Krivokapić, Z.. (2021). Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection. in Cancer Management and Research
Dove Medical Press Ltd, Albany., 13, 163-171.
https://doi.org/10.2147/CMAR.S287974

Bogdanović A, Despotović J, Galun D, Bidzić N, Nikolić A, Rosić J, Krivokapić Z. Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection. in Cancer Management and Research. 2021;13:163-171.
doi:10.2147/CMAR.S287974 .

Bogdanović, Aleksandar, Despotović, Jovana, Galun, Danijel, Bidzić, Nemanja, Nikolić, Aleksandra, Rosić, Jovana, Krivokapić, Zoran, "Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection" in Cancer Management and Research, 13 (2021):163-171,
https://doi.org/10.2147/CMAR.S287974 . .

TY  - JOUR
AU  - Rosić, Jovana
AU  - Dragičević, Sandra
AU  - Miladinov, Marko
AU  - Despotović, Jovana
AU  - Bogdanović, Aleksandar
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1469
AB  - Inhibitory SMAD7 and common mediator SMAD4 play crucial roles in SMAD-dependent TGF-I3 signaling that is often disrupted in colorectal cancer (CRC). This study aimed to profile the expression of SMAD7 and SMAD4 in primary and metastatic CRC and to evaluate their significance in disease progression and therapy response. The expression of SMAD7 and SMAD4 genes was analyzed by quantitative real-time PCR in tissues from 35 primary and metastatic CRC patients and in vitro in 7 human cell lines originating from colon tissue. Expression levels of SMAD7 and SMAD4, as well as their ratio, were determined and their association with tumor characteristics and response to therapy were evaluated. SMAD4 level was significantly lower in tumors compared to non-tumor tissues in both primary (p = 0.001) and metastatic (p = 0.001) CRC patients, while tumor expression of SMAD7 was significantly lower from non-tumor tissue only in metastatic patients (p = 0.017). SMAD7/SMAD4 ratio was elevated in CRC primary tumor tissues and cell lines compared to corresponding non-tumor tissues and cell line, respectively (p = 0.003). SMAD7 expression was significantly elevated in primary tumor tissues obtained from responders to neoadjuvant chemoradiotherapy (nCRT) compared to non-responders (p = 0.014). Alterations of expression and ratio of SMAD7 and SMAD4 in CRC cell lines, primary rectal cancer, and liver metastasis emphasize the importance of these genes in different stages of disease progression. Differential expression of SMAD7 in responders versus non-responders to nCRT should be further investigated for its potential predictive value.
PB  - Academic Press Inc Elsevier Science, San Diego
T2  - Experimental and Molecular Pathology
T1  - SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response
VL  - 123
DO  - 10.1016/j.yexmp.2021.104714
ER  - 

@article{
author = "Rosić, Jovana and Dragičević, Sandra and Miladinov, Marko and Despotović, Jovana and Bogdanović, Aleksandar and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2021",
abstract = "Inhibitory SMAD7 and common mediator SMAD4 play crucial roles in SMAD-dependent TGF-I3 signaling that is often disrupted in colorectal cancer (CRC). This study aimed to profile the expression of SMAD7 and SMAD4 in primary and metastatic CRC and to evaluate their significance in disease progression and therapy response. The expression of SMAD7 and SMAD4 genes was analyzed by quantitative real-time PCR in tissues from 35 primary and metastatic CRC patients and in vitro in 7 human cell lines originating from colon tissue. Expression levels of SMAD7 and SMAD4, as well as their ratio, were determined and their association with tumor characteristics and response to therapy were evaluated. SMAD4 level was significantly lower in tumors compared to non-tumor tissues in both primary (p = 0.001) and metastatic (p = 0.001) CRC patients, while tumor expression of SMAD7 was significantly lower from non-tumor tissue only in metastatic patients (p = 0.017). SMAD7/SMAD4 ratio was elevated in CRC primary tumor tissues and cell lines compared to corresponding non-tumor tissues and cell line, respectively (p = 0.003). SMAD7 expression was significantly elevated in primary tumor tissues obtained from responders to neoadjuvant chemoradiotherapy (nCRT) compared to non-responders (p = 0.014). Alterations of expression and ratio of SMAD7 and SMAD4 in CRC cell lines, primary rectal cancer, and liver metastasis emphasize the importance of these genes in different stages of disease progression. Differential expression of SMAD7 in responders versus non-responders to nCRT should be further investigated for its potential predictive value.",
publisher = "Academic Press Inc Elsevier Science, San Diego",
journal = "Experimental and Molecular Pathology",
title = "SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response",
volume = "123",
doi = "10.1016/j.yexmp.2021.104714"
}

Rosić, J., Dragičević, S., Miladinov, M., Despotović, J., Bogdanović, A., Krivokapić, Z.,& Nikolić, A.. (2021). SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response. in Experimental and Molecular Pathology
Academic Press Inc Elsevier Science, San Diego., 123.
https://doi.org/10.1016/j.yexmp.2021.104714

Rosić J, Dragičević S, Miladinov M, Despotović J, Bogdanović A, Krivokapić Z, Nikolić A. SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response. in Experimental and Molecular Pathology. 2021;123.
doi:10.1016/j.yexmp.2021.104714 .

Rosić, Jovana, Dragičević, Sandra, Miladinov, Marko, Despotović, Jovana, Bogdanović, Aleksandar, Krivokapić, Zoran, Nikolić, Aleksandra, "SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response" in Experimental and Molecular Pathology, 123 (2021),
https://doi.org/10.1016/j.yexmp.2021.104714 . .

TY  - CONF
AU  - Rosić, J.
AU  - Dragičević, Sandra
AU  - Miladinov, M.
AU  - Despotović, Jovana
AU  - Bogdanović, A.
AU  - Krivokapić, Z.
AU  - Nikolić, Aleksandra
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1452
PB  - Wiley, Hoboken
C3  - FEBS Open Bio
T1  - SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer
EP  - 433
SP  - 433
VL  - 11
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1452
ER  - 

@conference{
author = "Rosić, J. and Dragičević, Sandra and Miladinov, M. and Despotović, Jovana and Bogdanović, A. and Krivokapić, Z. and Nikolić, Aleksandra",
year = "2021",
publisher = "Wiley, Hoboken",
journal = "FEBS Open Bio",
title = "SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer",
pages = "433-433",
volume = "11",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1452"
}

Rosić, J., Dragičević, S., Miladinov, M., Despotović, J., Bogdanović, A., Krivokapić, Z.,& Nikolić, A.. (2021). SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer. in FEBS Open Bio
Wiley, Hoboken., 11, 433-433.
https://hdl.handle.net/21.15107/rcub_imagine_1452

Rosić J, Dragičević S, Miladinov M, Despotović J, Bogdanović A, Krivokapić Z, Nikolić A. SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer. in FEBS Open Bio. 2021;11:433-433.
https://hdl.handle.net/21.15107/rcub_imagine_1452 .

Rosić, J., Dragičević, Sandra, Miladinov, M., Despotović, Jovana, Bogdanović, A., Krivokapić, Z., Nikolić, Aleksandra, "SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer" in FEBS Open Bio, 11 (2021):433-433,
https://hdl.handle.net/21.15107/rcub_imagine_1452 .